Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints leading oncologist to board

Thomas Lynch is director of Yale Cancer Center

BMS Thomas LynchBristol-Myers Squibb (BMS) has appointed one of the world's leading oncologists to its board of directors.

Dr Thomas Lynch, who is currently director of the Yale Cancer Center, will join the pharma company's science and technology committee.

In addition to his role at Yale, Dr Lynch is also physician-in-chief at the Smilow Cancer Hospital at Yale-New Haven in the US, as well as professor of medical oncology at the same hospital.

Lamberto Andreotti, CEO of BMS, praised both Dr Lynch's work in cancer as well as his business leadership.

“As we advance our work in immuno-oncology and build our leadership position in oncology, his guidance and scientific and business perspectives will be invaluable,” said Andreotti.

Prior to his current roles at Yale, Dr Lynch was a professor of medicine at Harvard Medical School and chief of haematology and oncology at Massachusetts General Hospital (MGH) Cancer Center.

He also served as director of the Center for Thoracic Cancers at MGH and director of medical oncology at MGH Thoracic Oncology Center.

13th December 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics